ISSN 1004-5619
4 papers in the library · publishing 2024-2026
Fa yi xue za zhi April 25, 2026 Ruidi Shen, Zhenhua Qian
Abuse of mescaline and its analogues, a class of phenethylamine compounds often overlooked, has gradually increased worldwide. This review covers their basic information, pharmacological and toxicological properties, and detection methods, aiming to guide future research and provide references for forensic examination involving these substances.
Fa yi xue za zhi April 25, 2025 Yu-Meng Zuo, Wei Han, Jian-Bo Zhang et al.
Ketamine, a dissociative anesthetic used clinically for surgical anesthesia, can cause nerve damage, adverse emotional reactions, and other toxic side effects when abused. Its primary mechanism blocks N-methyl-D-aspartate receptors (NMDAR), but it also acts through multiple other pathways including AMPAR, opioid receptors, GABA receptors, monoaminergic receptors, cholinergic receptors, HCN channels, voltage-gated sodium channels, and L-type voltage-dependent calcium channels. This review summarizes the molecular mechanisms and toxic effects of ketamine to support forensic applications such as identifying symptomatic phenotypes of ketamine toxicity and detecting ketamine abuse.
Fa yi xue za zhi June 25, 2024 Jin-Ting Liu, Li-Ying Zhou, Jia-Hong Xiang et al.
Piperazines are a class of new psychoactive substances that produce hallucinogenic effects by altering monoamine neurotransmitter levels in the central nervous system. Their abuse causes stimulating and hallucinogenic effects along with adverse reactions such as headache, dizziness, anxiety, insomnia, vomiting, chest pain, tachycardia, hypertension, and may lead to cardiovascular diseases, multiple organ failure, and death. This review covers the in vivo processes, sample treatment, and analytical methods for piperazines, aiming to aid forensic identification.
Fa yi xue za zhi February 25, 2024 Wei-Guang Yu, Qiang He, Zheng-Di Wang et al.
After a single injection of MDMA in rats, peak concentrations of MDMA and its metabolite MDA occurred at 5 minutes and 1 hour, respectively, and both were detectable up to 12 hours. After continuous daily administration over 7 days, peak times shifted to 30 minutes for MDMA and 1.5 hours for MDA, and the detection window shortened to 10 hours. The ratio of MDMA to MDA in plasma followed a nonlinear relationship with time, described by separate equations for single and continuous dosing. These toxicokinetic differences provide reference data for forensic identification of MDMA exposure.